Volume up +900%...SP up +170%...During the 30 days preceding Dec 28, 2018 PressRelease there was roughly 2,5 million shares traded.
During the 30 days that follow Dec 28, 2018 PressRelease roughly 25 million shares were traded,an increase of 900% in volume with a share price increase of 170%.
The question is why this sudden interest in Genenews???
The answer could be that as far as 2014, Genenews had problems with its Billing Process, but most of all Genenews was unable to convince Insurances Companies to pay for Genenews tests.
The Dec 28, 2018 PressRelease seem to indicate that this problem is on the way to be resolved.
Dec 28, 2018 PressRelease Genenews said (QUOTE) '' Genenews expands coverage by Commercial health insurance network, resulting in expanded access to our four early cancer diagnostic tests...ColonSentry, EarlyCD lung, Prostate Health Index and BreastSentry''(End Of Quote).
It doesn't matter if ColonSentry is the best early detection blood cancer test in the word...it is worthless unless Insurance Companies are willing to pay for it.
It doesn't matter if Aristotle will be able to detect 10 cancers...it will be worthless unless Insurance Companies are willing to pay for it.
The Dec 28,2018 PressRelease was the missing link in this story. The comming on board of Insurances Companies(more to come) could have been what many investors were waiting for before investing in Genenews.
2019 should be a very interesting year.